INSEMPRA
26.7.2022 08:02:06 CEST | Business Wire | Press release
Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd (‘Solena’), a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers.
The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating naturally superior products to drive the regenerative revolution. Solena will be a major part of Insempra’s platform to deliver high-performance, intrinsically sustainable ingredients for a broad array of industries.
Solena is using computational design to develop new classes of synthetic proteins to produce high-performance clothing fibers, which can absorb large amounts of kinetic energy. Insempra will accelerate the development and production of these synthetic proteins on an industrial scale, offering better, biobased solutions to the petrochemically sourced, non-biodegradable materials or fibers extracted from nature or animals, such as silk, currently used in the textile and clothing industries. This technology also reduces other environmental impacts such as the rise of microplastics in water bodies coming from washing petrochemically-sourced textiles.
Jens Klein, founder and CEO of Insempra and CEO of Solena Materials, commented: “We are hugely excited by this investment in Solena, which will help to accelerate our market-first approach to develop superior, intrinsically sustainable ingredients. We look forward to fast-tracking Solena’s development and production of their unique synthetic proteins to develop customized, high-performance fibers for a variety of applications.”
Dr James MacDonald, inventor, co-founder and CTO of Solena Materials, added: “The team and I are very excited to make this technology a huge success.”
Professor Paul Freemont of Imperial College London, added: “This investment from Insempra recognizes the potential of our technology to revolutionize high-performance fabrics, and their supply chains. Together, we can harness our synthetic biology capabilities to develop, produce and manufacture a new class of superior, more sustainable fiber technology.”
Insempra, a co-founder of Solena, will be the sole contributing shareholder in Solena, which is based at Imperial College’s Translation & Innovation Hub (I-HUB) in White City, London. Solena’s Board will be comprised of Dr James MacDonald of Solena, Professor Paul Freemont and Professor Milo Shaffer of Imperial College London, and Jens Klein and Andreas Heyl of Insempra.
About Insempra
Insempra is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.
For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.
Led by a hand-picked team of biologists, technologists and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.
Learn more about Insempra at insempra.bio
About Solena Materials
Solena is a protein materials design company. We use world-leading computational design, machine learning, and automation to accelerate the development of bespoke materials targeted at multiple sectors, from fashion apparel to medical textiles. Our new protein-based fibers will replace materials extracted from nature such as silk and petrochemically-derived materials, to create a new world of biodegradable, functional and sustainable smart materials for consumers, industry, and the planet.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005756/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom